We were delighted to talk to Professor Claudia Fox (University of Minnesota, Minneapolis, MN, US) around the use of exenatide for weight loss maintenance among adolescents with severe obesity.
‘Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial.‘ (PRESENTATION NUMBER: OR02-4) was presented at the ENDO 2021 Virtual Annual Meeting, March 20 – 23, 2021.
Questions
- What are the major challenges to weight loss maintenance among adolescents with severe obesity? (0:25)
- What is the rationale for the use of exenatide in non-diabetic obese adolescents? (2:26)
- Could you tell us a little about the aims, design and inclusion criteria of your study? (4:08)
- What were the efficacy and safety findings of the study? (5:39)
- What are the implications of these findings for the routine use of exenatide for weight loss maintenance among adolescents with severe obesity, and what questions remain unanswered? (7:52)
Disclosures: Claudia Fox discloses receiving research support from Novo Nordisk and Rhythm Pharmaceuticals.
Support:Â Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ENDO 2021 (Virtual).
